Life-saving effect of convalescent plasma treatment in covid-19 disease: Clinical trial from eastern Anatolia.
Convalescent plasma
Coronavirus
Covid-19
Immun plasma
Sars-Cov-2 infection
Journal
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
ISSN: 1473-0502
Titre abrégé: Transfus Apher Sci
Pays: England
ID NLM: 101095653
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
15
06
2020
revised:
18
06
2020
accepted:
19
06
2020
pubmed:
6
7
2020
medline:
15
12
2020
entrez:
5
7
2020
Statut:
ppublish
Résumé
Convalescent Plasma (CP) therapy is of interest as no vaccine or specific treatment is available for emerging viruses such as severe acute respiratory syndrome coronavirus 2 causing Covid-19. It was aimed to report the results of our patients who underwent CP in the treatment of Covid-19. CP treatment was applied to 26 Covid-19 patients in intensive care unit who had quantitative reverse transcriptase-polymerase chain reaction positive Sars-Cov-2 infection. Plasma was collected at least 14 days after complete recovery from patients who had mild or moderate infection with Sars-Cov-2 infection. The collected CP (200cc) were applied to severe Covid-19 patients. Laboratory values of patients just before CP and after 7 days were compared. There were no statistically significant differences in leukocyte, neutrophil, lymphocyte, platelet, CRP, ferritin, LDH, ALT, AST, sO CP therapy has the potential to provide immediate and promising treatment options before specific vaccines and treatments are developed. In early stage Covid-19 patients who do not need mechanical ventilation, CP treatment may be a curative treatment option.
Identifiants
pubmed: 32620409
pii: S1473-0502(20)30172-5
doi: 10.1016/j.transci.2020.102867
pmc: PMC7320698
pii:
doi:
Types de publication
Clinical Trial
Journal Article
Langues
eng
Pagination
102867Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Références
Clin Infect Dis. 2011 Feb 15;52(4):447-56
pubmed: 21248066
Transfus Apher Sci. 2020 Jun;59(3):102790
pubmed: 32345485
J Antimicrob Chemother. 2005 Nov;56(5):919-22
pubmed: 16183666
JAMA. 2020 Apr 28;323(16):1582-1589
pubmed: 32219428
Chest. 2020 Jul;158(1):e9-e13
pubmed: 32243945
Clin Microbiol Infect. 2004 Jul;10(7):676-8
pubmed: 15214887
Lancet Infect Dis. 2020 Apr;20(4):398-400
pubmed: 32113510
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496
pubmed: 32253318
Antivir Ther. 2018;23(7):617-622
pubmed: 29923831
JAMA. 2020 Aug 4;324(5):460-470
pubmed: 32492084
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
N Engl J Med. 2016 Jan 7;374(1):33-42
pubmed: 26735992
J Korean Med Sci. 2020 Apr 13;35(14):e149
pubmed: 32281317
J Clin Invest. 2020 Apr 1;130(4):1545-1548
pubmed: 32167489